In short
This article discusses the use of Quinine Dihydrochloride in clinical trials for Parkinson's Disease (PD). While the primary focus of the trial is on another drug called Fasudil, Quinine Dihydrochloride is mentioned as a comparator or reference drug. The study aims to evaluate the safety, tolerability, and potential efficacy of these medications in managing PD symptoms.
At a glance
- Study Drug
- Quinine Dihydrochloride (solution for injection)
- Condition Studied
- Idiopathic Parkinson's Disease
- Trial Phase
- Phase II
- Main Objective
- Evaluate safety, tolerability, and potential efficacy
- Treatment Duration
- Maximum 22 days
- Key Inclusion Criteria
- Age 30-80, diagnosed PD, Hoehn & Yahr stage 1-3
- Primary Outcome Measures
- Treatment-related adverse events and tolerability
- Secondary Outcome Measures
- Changes in MDS-UPDRS, PDQ-8, NMSQuest, MoCA, BDI-II
What is Quinine Dihydrochloride?
Quinine Dihydrochloride is a medication that has been used in various medical treatments. It is a form of quinine, which is derived from the bark of the cinchona tree. In the context of this article, we will discuss its use as mentioned in a clinical trial document.
Medical Uses
While the primary focus of the clinical trial document is not on Quinine Dihydrochloride, it is mentioned as a comparator drug. The main study is actually about a different medication called Fasudil, which is being tested for Parkinson's disease. However, the presence of Quinine Dihydrochloride in this context suggests that it may have some relevance to neurological conditions or serve as a reference point for the study.
Traditionally, Quinine Dihydrochloride is known for its use in treating malaria. This is supported by its ATC code P01BC01, where P01 refers to antiprotozoals, and BC specifically to methanolquinolines, a class of antimalarial drugs.
Administration
According to the clinical trial information, Quinine Dihydrochloride is available as a solution for injection. The specific product mentioned is "Quinina Labesfal 250 mg/ml Solução injetável" (Quinine Labesfal 250 mg/ml Injectable Solution).
However, it's important to note that for the purposes of the study, the administration route is listed as oral. This suggests that the injectable solution is being modified for oral use in this particular context.
Dosage
The clinical trial document provides some information about the dosage used in the study:
- The maximum daily dose amount is listed as 2 (units not specified).
- The maximum total dose amount over the course of treatment is 42 (units not specified).
- The maximum treatment period is 22 days.
It's crucial to understand that these dosages are specific to this clinical trial and may not reflect standard treatment protocols. Always follow your doctor's instructions regarding dosage and administration.
Important Considerations
The clinical trial document mentions some important points about the use of Quinine Dihydrochloride in this study:
- Dilution: The medication is diluted before use. Specifically, 0.05 ml of Quinine Dihydrochloride is mixed with 30 ml of 40% glucose solution immediately before use.
- Packaging and Labeling: The product undergoes changes in packaging and labeling for the purposes of the study.
- Chemical Nature: Quinine Dihydrochloride is classified as a chemical substance, not derived from biological sources.
It's important to note that this information is based on a specific clinical trial and may not reflect the typical use of Quinine Dihydrochloride in general medical practice. Always consult with a healthcare professional for accurate information about your specific treatment.